

STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

#5 1653
Docket No.
098810/027 8741

RECEIVED

In Re Application Of: • Warren, et al.

AUG 29 2001
PATENT & TRADEMARK OFFICE

AUG 31 2001

TECH CENTER 1600/2900

Serial No.
09/813,383

Filing Date
March 20, 2001

Examiner
NYA

Group Art Unit
1653

Invention: PEPTIDE SPECIFICITY OF ANTI-MYELIN BASIC PROTEIN AND THE ADMINISTRATION OF
MYELIN BASIC PROTEIN PEPTIDES TO MULTIPLE SCLEROSIS PATIENTS

TO THE ASSISTANT COMMISSIONER FOR PATENTS:

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

Statement Under 37 CFR 1.97(e)(1)

- ☒ Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Statement Under 37 CFR 1.97(e)(2)

- ☐ No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Robert M. Bedgood
Signature

Dated: August 22, 2001

Robert M. Bedgood (Reg. No. 43,488)

Certificate of Mailing by First Class Mail

I certify that this document is being deposited on
August 25, 2001 with the U.S. Postal Service as first
class mail under 37 C.F.R. 1.8 and is addressed to the
Assistant Commissioner for Patents, Washington, D.C.
20231.

Danielle J. Moten
Signature of Person Mailing Correspondence

Danielle J. Moten

Typed or Printed Name of Person Mailing Correspondence

cc: SF Docketing